Company intelligence / Profile preview

BicycleTx Limited

Cambridge, Cambridgeshire, United Kingdom

Ownership: Private
Employees: ~170
Development stage: Other

Overview

Bicycle Therapeutics' lead program, BT1718, is in Phase 1/2a clinical trials in partnership with Cancer Research UK for advanced solid tumors targeting MT1-MMP. Early clinical studies are assessing safety, pharmacokinetics, and signals of efficacy. No immunogenicity has been observed to date, and the platform's tumor-penetrating properties are highlighted as key strengths.

Therapeutic areas: Oncology
Modalities: Bicyclic peptidesSmall moleculePeptidesPeptide-drug conjugate
Industry: Biotech

Partnerships

AstraZenecaOxurionInnovate UKDementia Discovery FundCancer Research UK

Beyond the preview

Go deeper on BicycleTx Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BicycleTx Limited.

Explore the full profile